Alison Balfour

469 total citations
11 papers, 348 citations indexed

About

Alison Balfour is a scholar working on Pediatrics, Perinatology and Child Health, Immunology and Nephrology. According to data from OpenAlex, Alison Balfour has authored 11 papers receiving a total of 348 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pediatrics, Perinatology and Child Health, 5 papers in Immunology and 4 papers in Nephrology. Recurrent topics in Alison Balfour's work include Biosimilars and Bioanalytical Methods (5 papers), Pharmaceutical studies and practices (5 papers) and Health Systems, Economic Evaluations, Quality of Life (4 papers). Alison Balfour is often cited by papers focused on Biosimilars and Bioanalytical Methods (5 papers), Pharmaceutical studies and practices (5 papers) and Health Systems, Economic Evaluations, Quality of Life (4 papers). Alison Balfour collaborates with scholars based in United States, Switzerland and France. Alison Balfour's co-authors include Eduardo Mysler, Jozef Rovenský, Hsiao‐Yi Lin, A. So, Marc De Meulemeester, Gerhard Krammer, Udayasankar Arulmani, Peter Sallstig, Naomi Schlesinger and Andrew Blauvelt and has published in prestigious journals such as Journal of Allergy and Clinical Immunology, Annals of the Rheumatic Diseases and The American Journal of Gastroenterology.

In The Last Decade

Alison Balfour

11 papers receiving 331 citations

Peers

Alison Balfour

NEPHR

IMMUN

RHEUM

SURGE

Rakhi Seth United Kingdom

Juliana Caires de Oliveira Achili Ferreira Brazil

Nuray Özkaya Türkiye

J. M. Cruzado Spain

Utis Deesomchok Thailand

Engin Melek Türkiye

Gérard Cam France

Simon Kok Jensen Denmark

Kaori Muro Japan

Vincenzo Di Leo Italy

Rakhi Seth United Kingdom

Alison Balfour

123 ×0.8

NEPHR

38 ×0.2

IMMUN

149 ×1.5

RHEUM

27 ×0.3

90 ×1.0

SURGE

Citations per year, relative to Alison Balfour Alison Balfour (= 1×) peers Rakhi Seth

Countries citing papers authored by Alison Balfour

Since Specialization

Citations

This map shows the geographic impact of Alison Balfour's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alison Balfour with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alison Balfour more than expected).

Fields of papers citing papers by Alison Balfour

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alison Balfour. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alison Balfour. The network helps show where Alison Balfour may publish in the future.

Co-authorship network of co-authors of Alison Balfour

This figure shows the co-authorship network connecting the top 25 collaborators of Alison Balfour. A scholar is included among the top collaborators of Alison Balfour based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alison Balfour. Alison Balfour is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Balfour, Alison, et al.. (2022). Staphylococcus lugdunensis in children: A retrospective analysis. Pediatric Investigation. 6(3). 163–170. 2 indexed citations

Blauvelt, Andrew, et al.. (2021). Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS). BioDrugs. 35(2). 229–238. 11 indexed citations

Wiland, Piotr, et al.. (2021). AB0208 DO LOW CONCENTRATIONS OF CITRATE IN AN ADALIMUMAB FORMULATION IMPACT THE INCIDENCE AND/OR INTENSITY OF INJECTION SITE PAIN? DATA FROM PHASE I AND III STUDIES ASSESSING THE LOCAL TOLERANCE OF GP2017 (ADALIMUMAB BIOSIMILAR, SDZ-ADL) IN HEALTHY VOLUNTEERS, RHEUMATOID ARTHRITIS, AND PSORIASIS PATIENTS. Annals of the Rheumatic Diseases. 80. 1130–1131. 1 indexed citations

Richter, Oliver von, et al.. (2019). Differences in immunogenicity associated with non-product related variability: insights from two pharmacokinetic studies using GP2017, an adalimumab biosimilar. Expert Opinion on Biological Therapy. 19(10). 1057–1064. 6 indexed citations

Blauvelt, Andrew, J.‐P. Lacour, Joseph F. Fowler, et al.. (2018). Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. British Journal of Dermatology. 179(3). 623–631. 109 indexed citations

Blauvelt, Andrew, et al.. (2017). Long-term Efficacy, Safety, and Immunogenicity Data From a Phase III Confirmatory Study Comparing GP2017, a Proposed Biosimilar, With Reference Adalimumab. The American Journal of Gastroenterology. 112. S419–S419. 10 indexed citations

Tönshoff, Burkhard, Lars Pape, Robert B. Ettenger, et al.. (2012). Early Conversion of Calcineurin Inhibitor to Everolimus in De Novo Paediatric Renal Transplant Recipients and Its Impact on Efficacy and Renal Function; Design of An Open-Label, Randomised, Multi-Centre Study. Transplantation. 94(10S). 1208–1208. 3 indexed citations

Schlesinger, Naomi, Eduardo Mysler, Hsiao‐Yi Lin, et al.. (2011). Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Annals of the Rheumatic Diseases. 70(7). 1264–1271. 175 indexed citations

Meulemeester, Marc De, A. Pikhlak, Eftal Yücel, et al.. (2011). Metabolic and crystal arthropathies: 112. Rapid Improvement in Health-Related Quality of Life in Gouty Arthritis Patients Treated with Canakinumab (ACZ885) Compared to Triamcinolone Acetonide. Lara D. Veeken. 50(Supplement 3). iii85–iii86. 3 indexed citations

10.

Hexham, J. Mark, et al.. (2011). Efficacy and safety of SBR759, a novel calcium‐free, iron(III)‐based phosphate binder, in Asian patients undergoing hemodialysis: A 12‐week, randomized, open‐label, dose‐titration study versus sevelamer hydrochloride. Nephrology. 16(8). 743–750. 21 indexed citations

11.

Schlesinger, Naomi, Eduardo Mysler, Jozef Rovenský, et al.. (2011). Canakinumab Reduces The Risk Of Acute Gouty Arthritis Flares During Initiation Of Allopurinol Therapy: Results Of A Double-blind, Randomised Study. Journal of Allergy and Clinical Immunology. 127(2). AB227–AB227. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact